The purpose of this study is to evaluate a potential long-acting injectable HIV treatment option for people whose HIV is not undetectable.

The study drug is a long-acting HIV treatment. It is given by injection every other month after 2 started doses. This is in contrast to oral ART, which is designed to be taken daily.

This study is comparing rectal and oral Tenofavir-based prep. The rectal study product is a rectal douche, or enema, that contains the anti-HIV drug tenofovir (TFV). The other study product is taken by mouth and is a combination of two drugs, called emtricitabine (FTC or F) and tenofovir disoproxil fumarate (TDF).

Tenofovir (TFV) rectal douche is considered investigational because it is not approved by the U.S. Food and Drug Administration (FDA). Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) is FDA-approved and used according to FDA labeling.

The purpose of this study is to facilitate the consent, collection, and research use of biospecimens and data for profiling of immune cells and research from patients seen by physicians at Weill Cornell Medical College/New York-Presbyterian who are screened for, consented to, and undergo tumor-infiltrating lymphocyte (TIL) cellular therapy for solid tumor malignancies.
   

This clinical trial is for adults who have congenital antithrombin deficiency (which is a disorder of blood clotting) and who are scheduled to undergo surgery OR childbirth in the near future.
   

 This clinical trial is for adults who have been diagnosed with one of the following relapsed or refractory (R/R) B-cell malignancies: non-germinal center B-cell diffuse large B-cell lymphoma (non-GCB DLBCL), follicular lymphoma (FL), Richter’s Transformation (RT), Waldenstrom macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL).
   

This study is being done to evaluate if the combination of ASTX727 and venetoclax works better than ASTX727 alone at decreasing the signs and symptoms of bone marrow cancer, known as myelodysplastic/myeloproliferative neoplasm (MDS/MPN).

We are doing this study because we want to find out if this approach is better or worse than the usual approach for bone marrow cancer called chronic myelomonocytic leukemia (CMML) or a less common form called non-CMML MDS/MPN. The usual approach is defined as care most people get.

The primary objective of the study is to understand how common fatty liver disease, which has a new updated name called Steatotic Liver Disease (SLD) or metabolic dysfunction associated steatotic liver disease (MASLD), is seen in pregnant people and if it affects pregnancy health and outcomes. This study assesses liver health throughout pregnancy and after delivery. 
   

The purpose of this study is to evaluate the efficacy of adding cusatuzumab to venetoclax plus azacitidine (VAC) compared to venetoclax plus azacitidine (VA) alone for patients with acute myeloid leukemia (AML).

Cusatuzumab is considered investigational which means it has not been approved by the U.S. Food and Drug Administration (FDA). Azacitidine and venetoclax are both FDA-approved.   

This is a randomized clinical research study examining an investigational treatment called CVN424 in patients with Parkinson's Disease (PD).

This phase 3 program is evaluating the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn’s Disease.